Epigenetic Control of Regulatory T Cell Stability and Function: Implications for Translation.

Autor:	Joudi AM; Department of Medicine, Division of Pulmonary and Critical Care Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.; Canning Thoracic Institute, Northwestern University Feinberg School of Medicine, Chicago, IL, United States., Reyes Flores CP; Department of Medicine, Division of Pulmonary and Critical Care Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.; Canning Thoracic Institute, Northwestern University Feinberg School of Medicine, Chicago, IL, United States., Singer BD; Department of Medicine, Division of Pulmonary and Critical Care Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.; Canning Thoracic Institute, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.; Department of Biochemistry and Molecular Genetics, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.; Simpson Querrey Institute for Epigenetics, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in immunology [Front Immunol] 2022 Mar 02; Vol. 13, pp. 861607. Date of Electronic Publication: 2022 Mar 02 (Print Publication: 2022).
DOI:	10.3389/fimmu.2022.861607
Abstrakt:	FoxP3 + regulatory T (Treg) cells maintain immune homeostasis, promote self-tolerance, and have an emerging role in resolving acute inflammation, providing tissue protection, and repairing tissue damage. Some data suggest that FoxP3 + T cells are plastic, exhibiting susceptibility to losing their function in inflammatory cytokine-rich microenvironments and paradoxically contributing to inflammatory pathology. As a result, plasticity may represent a barrier to Treg cell immunotherapy. Here, we discuss controversies surrounding Treg cell plasticity and explore determinants of Treg cell stability in inflammatory microenvironments, focusing on epigenetic mechanisms that clinical protocols could leverage to enhance efficacy and limit toxicity of Treg cell-based therapeutics. Competing Interests: BS holds United States Patent No. US 10,905,706 B2, “Compositions and Methods to Accelerate Resolution of Acute Lung Inflammation,” and serves on the Scientific Advisory Board of Zoe Biosciences, in which he holds stock options. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Joudi, Reyes Flores and Singer.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu